Transtelephonic Spirometry

LCD Information Document Information Source LCD ID N/A LCD ID L34541 Original ICD-9 LCD ID Not Applicable LCD Title Transtelephonic Spirometry Proposed LCD in Comment Period N/A Source Proposed LCD DL34541 Opens in a new window Original Effective Date For services performed on or after 10/01/2015 Revision Effective Date For services performed on or after 10/02/2025 Revision Ending Date N/A Retirement Date N/A Notice Period Start Date 01/05/2023 Notice Period End Date 02/18/2023 CPT codes, descriptions, and other data only are copyright 2025 American Medical Association. All Rights Reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association. Current Dental Terminology © 2025 American Dental Association. All rights reserved. Copyright © 2026, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at ub04@aha.org or 312‐422‐3366. Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates. Issue Issue Description This LCD outlines limited coverage for this service with specific details under Coverage Indications, Limitations, and/or Medical Necessity. Issue - Explanation of Change Between Proposed LCD and Final LCD CMS National Coverage Policy Language quoted from Centers for Medicare and Medicaid Services (CMS), National Coverage Determinations (NCDs) and coverage provisions in interpretive manuals is italicized throughout the policy. NCDs and coverage provisions in interpretive manuals are not subject to the Local Coverage Determination (LCD) Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See Section 1869(f)(1)(A)(i) of the Social Security Act.Unless otherwise specified, italicized text represents quotation from one or more of the following CMS sources:Title XVIII of the Social Security Act (SSA):Section 1862(a)(1)(A) excludes expenses incurred for items or services, which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.Section 1833(e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim. Code of Federal Regulations:42 CFR, 410.32, indicates that diagnostic tests may only be ordered by the treating physician (or other treating practitioner acting within the scope of his or her license and Medicare requirements) who furnishes a consultation or treats a beneficiary for a specific medical problem and who uses the results in the management of the beneficiary's specific medical problem. Tests not ordered by the physician (or other qualified non-physician provider) who is treating the beneficiary are not reasonable and necessary (see Sec. 411.15(k)(1) of this chapter). Coverage Indications, Limitations, and/or Medical Necessity Spirometry is a non-invasive technique that measures the vital capacity, forced expired volume in one second, and rates airflow at various lung volumes. Measurement of the forced vital capacity and corresponding flow rates is the most commonly used test to detect the presence of lung disease and to monitor changes in severity and response to treatment. Patient-initiated spirometric recording per 30-day period of time includes reinforced education, transmission of spirometric tracing, data capture, analysis of transmitted data, periodic recalibration and physician review and interpretation. The use of peak flow meters by patients, and their recording and reporting of the results to their physician, has been a standard means of monitoring patients with pulmonary dysfunction at home. Transtelephonic spirometry has also been investigated in lung heart-lung transplant recipients who underwent monitoring of lung rejection with home spirometry. Scientific conclusions support the utility of home monitoring in this clinical setting. Home spirometry and telespirometry is considered reasonable and medically necessary for lung transplant recipients when the following is met: 1.Lung transplant patient 2. Adherence to home spirometry measurements of ≥80%. This is defined by transmission of data at least 80% of the time. 3. If patient is non-compliant* then they are not eligible for further home spirometry services. *Non-compliance is defined as no measurements or transmitted for 7 consecutive days x 2. If they are non-compliant for one week the coordinator can reach out and offer education. If non-compliance continues (no measurement for 7 days) then the service will no longer be eligible for coverage. Home spirometry and telespirometry is considered experimental and investigational for all other indications (asthma, idiopathic pulmonary fibrosis, and persons with other chronic pulmonary diseases/disorders (e.g., emphysema)) because there is a lack of evidence that it will improve the care of persons with these disorders. Summary of Evidence A consensus report from the Pulmonary Council of the International Society for Heart and Lung Transplantation (ISHLT) set out to standardize the nomenclature of chronic lung allograft dysfunction (CLAD) and its clinical phenotypes to facilitate collaboration among centers investigating the pathogenesis, prevention, and treatment of CLAD.1 CLAD is defined as a substantial and persistent decline (≥20%) from baseline in measured FEV1. The baseline value is computed as the mean of the best 2 post-operative FEV1 measurements (taken >3 weeks apart). CLAD can present either as a predominantly obstructive ventilatory pattern, a restrictive pattern, or a mixed obstructive and restrictive pattern that is not explained by other conditions. Consistent pulmonary function testing (PFT) is the leading strategy for early detection of CLAD. While home spirometry devices may provide more variable results, evidence supports it as a useful modality to detect early changes in graft function and may assist providers in decision making. A systematic review was conducted to determine the effectiveness of home spirometry as a bronchiolitis obliterans syndrome (BOS) detection tool in lung transplant recipients. Eight randomized control trials were included. Authors conclude that home spirometry may be a reliable and safe alternative for lung transplant recipients although they acknowledge the study did not address the impact of early detection on survival outcomes.2 Finkelstein et al. performed a randomized control trial to determine the relative performance of a computer-based Bayesian triage algorithm compared with a manual nurse-based triage system in terms of patient health and health-related quality of life (QOL) in lung transplant recipients. The trial had 65 lung transplant recipients assigned to either the Bayesian algorithm or nurse triage study arm. Subjects monitored and transmitted spirometry and respiratory symptoms daily to the data center using an electronic spirometer/diary device. Subjects completed the Short Form-36 (SF36) survey at baseline and after 1 year. End points were change from baseline after 1 year in forced expiratory volume at 1 second (FEV1) and quality of life (SF-36 scales) within and between each study arm. A total of 65 subjects (control arm=35, intervention arm=30) yielded an overall adherence of 83% for data collection and 88% adherence during the first year. No significant differences in physical (FEV1) or quality of life (SF-36) measures from baseline after HM triage follow-up for subjects in the two arms, suggesting that subjects’ physiological and functional outcomes were similar regardless of the triage method used to monitor HM data. 3 Fadaizadeh et al. conducted pilot study to evaluate the role of home spirometry in follow up of lung transplant recipients and early detection of complications over a 6-month period. Four subjects were included with 2 of those being matched control subjects. Adherence was 80% and 61% in the active participants. The authors conclude that HS is a viable method for monitoring.4 The team conducted further investigation with a prospective cohort study on 15 lung transplant recipients to assess patient adherence and satisfaction with telespirometry following lung transplant over 6 months. Study participants were instructed to send home spirometry results and their clinical symptoms via SMS message. Patients’ level of satisfaction showed a sense of increased support from medical staff was rated highest (92.9%) while satisfaction with the spirometer was rated lowest (35.7%). Average patient compliance at baseline was 80% compared to 27% at study completion, resulting in an average of 78% throughout the study duration. Authors conclude telespirometry is an efficient method of monitoring lung transplant recipients with increased patient satisfaction and adherence.5 A single center retrospective cohort study included 427 adult patients that received the first lung transplantation (LTx) in a specialized outpatient clinic between 1-1-2010 and 12-31-2013. The primary outcome was allograft survival. The secondary outcomes were patient survival, prevalence of CLAD, hospitalizations within the first year after transplantation, renal function after 5 years, and quality of life within the first 3 years after transplantation. The median adherence was 86% on 6,623 visits and was used as the cut off and as a discriminator between good and suboptimal adherers. Patients with good adherence within the first 3 years yielded more favorable 5-year allograft results (74% vs. 60%, p = 0.003) and patient survival (79% vs. 64%, p<0.001) and lower prevalence of chronic allograft dysfunction (33% vs. 45%, p = 0.011) after 5 years when compared to patients with suboptimal adherence.6 A single center retrospective study of adult lung transplant recipients on long term azithromycin for bronchiolitis obliterans (BOS) was performed to evaluate if macrolide-refractory progression could be identified earlier with home spirometry (HS) compared to office spirometry (OS). A total of 239 lung transplant patients were included. Change in FEV1 +/- 10% from FEV1 at azithromycin initiation for >7 consecutive days in HS or >2 measures in OS were taken as cut-off for response or progression. 67% (161/239) demonstrated progression and an additional 8% (n=19) showed initial response followed by relapse. Time to progression was 29 (13-96) days earlier with HS than in OS. Response or stabilization conferred significant improvement in survival (p=0.005). Authors concluded HS identified azithromycin refractory patients significantly earlier than OS, possibly facilitating aggressive treatment escalation that may improve long-term outcome.7 An observational feasibility study was performed to explore the feasibility of rural home telemonitoring for patients with lung cancer. Five patients received usual care after discharge; and five had telemonitors set up at home for 14 days with daily phone calls for nurse coaching; mid- and end-study data were collected by phone and in homes through two months. One of 5 usual care and 3 of 5 monitored patients completed the study. Authors concluded telemonitored data transmission was feasible in rural areas with high satisfaction and symptom data and physiologic data were inconsistent based on disease. 8 Limitations included small sample size and short-term follow-up. Wang and associates explored new computer-based approaches for the early detection of bronchopulmonary events in a population of lung transplant recipients following a home monitoring protocol. Twenty-eight transplant recipients had a minimum home monitoring period of 60 days. Spirometry and clinical data were collected daily at home by lung transplant recipients and transmitted weekly to the study data center. The majority of event were captured using forced expiratory volume in 1 second or symptoms (sensitivity, 80–90%) at an acceptable level of false alarms. Mean detections occurred 6.6–10.8 days earlier than the known event records. Based on these findings, the authors concluded the approach was useful for early discovery of pulmonary events.9 According to UpToDate, many centers utilize routine home spirometry but note the limitation of patient compliance with this modality is inconsistent.10 Analysis of Evidence (Rationale for Determination) The current literature on the use of transtelephonic spirometry suggests limitations of patient compliance and potential issues with spirometry equipment calibration. Despite these obstacles, patients show benefits from the early detection of pulmonary complications and provider awareness. Based on the emergence of supporting literature and societal guidance coverage for transtelephonic spirometry for lung transplant patients is considered reasonable and medically necessary.

Spirometry is a non-invasive technique that measures the vital capacity, forced expired volume in one second, and rates airflow at various lung volumes. Measurement of the forced vital capacity and corresponding flow rates is the most commonly used test to detect the presence of lung disease and to monitor changes in severity and response to treatment. Patient-initiated spirometric recording per 30-day period of time includes reinforced education, transmission of spirometric tracing, data capture, analysis of transmitted data, periodic recalibration and physician review and interpretation. The use of peak flow meters by patients, and their recording and reporting of the results to their physician, has been a standard means of monitoring patients with pulmonary dysfunction at home. Transtelephonic spirometry has also been investigated in lung heart-lung transplant recipients who underwent monitoring of lung rejection with home spirometry. Scientific conclusions support the utility of home monitoring in this clinical setting. Home spirometry and telespirometry is considered reasonable and medically necessary for lung transplant recipients when the following is met: 1.Lung transplant patient 2. Adherence to home spirometry measurements of ≥80%. This is defined by transmission of data at least 80% of the time. 3. If patient is non-compliant* then they are not eligible for further home spirometry services. *Non-compliance is defined as no measurements or transmitted for 7 consecutive days x 2. If they are non-compliant for one week the coordinator can reach out and offer education. If non-compliance continues (no measurement for 7 days) then the service will no longer be eligible for coverage. Home spirometry and telespirometry is considered experimental and investigational for all other indications (asthma, idiopathic pulmonary fibrosis, and persons with other chronic pulmonary diseases/disorders (e.g., emphysema)) because there is a lack of evidence that it will improve the care of persons with these disorders.